The Food and Drug Administration has given the regulatory greenlight to IDX Systems for its IDXview image management product.IDXview represents the Burlington, VT, company's effort to expandfrom its base in radiology information systems into digital
The Food and Drug Administration has given the regulatory greenlight to IDX Systems for its IDXview image management product.IDXview represents the Burlington, VT, company's effort to expandfrom its base in radiology information systems into digital imagemanagement, according to Britt Cummings, manager of radiologysystems.
IDXview is based on Digital Equipment Alpha workstation architecturerunning an X-Windows operating system with 1k x 1k display monitors.It is DICOM-compliant and can be integrated with the company'sIDXrad RIS product, making it one of the first commercially availableintegrated RIS/image management solutions.
IDXview is not a PACS product, Cummings said, because it lacksthe 2k x 2k monitor technology required for primary diagnosis.Instead, IDX will market the system as ideal for consultationand review between radiology departments and referring physiciansin other areas. A primary diagnosis component can be added vialinks to PACS products from other vendors, he said.
IDX will emphasize the integrated nature of the RIS and imagemanagement system in marketing IDXview. IDXrad has a sophisticatedsearch engine that makes it easy for physicians to locate andsort patient data, according to Cummings.
"Because we are so tied to the RIS, we have some verysimple and efficient searches to find the patient (physicians)are looking for," Cummings said.
There are two beta sites using IDXview and the company is readyto begin shipping the product.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.